MktsMarkets

TG Therapeutics, Inc.
NASDAQ: TGTXKey statistics
TGTX News
Stories mentioning TGTX from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 204,918 | 192,574 | 161,709 | 141,148 | 120,856 | 108,185 | 83,879 | 73,466 |
| Cost of Goods Sold | 33,510 | 38,142 | 28,093 | 18,938 | 15,541 | 15,400 | 9,341 | 8,304 |
| Gross Profit | 171,408 | 154,432 | 133,616 | 122,210 | 105,315 | 92,785 | 74,538 | 65,162 |
| Operating Expenses | ||||||||
| Research & Development | 48,396 | 41,193 | 40,878 | 31,782 | 46,362 | 23,875 | 20,138 | 17,556 |
| Sales General & Admin | 88,217 | 62,745 | 63,373 | 55,585 | 50,331 | 38,961 | 41,966 | 38,790 |
| Total Operating Expenses | ||||||||
| Operating Income (Loss) | 34,795 | 50,494 | 29,365 | 34,843 | 8,622 | 29,949 | 12,434 | 8,816 |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | 2,387 | 1,132 | 3,265 | 2,793 | 3,603 | 2,435 | 2,666 | 1,712 |
| Pretax Income | 20,363 | 45,093 | 25,909 | 30,920 | 5,468 | 25,453 | 4,268 | 6,551 |
| Tax Provision | 586.00 | 22,056 | (364,986) | 2,733 | 408.00 | 2,122 | 388.00 | (328.00) |
| Net Income (Loss) | 19,777 | 23,037 | 390,895 | 28,187 | 5,060 | 23,331 | 3,880 | 6,879 |
| Earnings Per Share (Basic) | 0.14 | 0.16 | 2.69 | 0.19 | 0.03 | 0.16 | 0.03 | 0.05 |
| Earnings Per Share (Diluted) | 0.12 | 0.14 | 2.43 | 0.17 | 0.03 | 0.15 | 0.02 | 0.04 |
| Weighted Average Shares Outstanding (Basic) | 144,439 | 144,317 | 145,417 | 146,740 | 146,678 | 145,317 | 145,102 | 144,727 |
| Weighted Average Shares Outstanding (Diluted) | 160,062 | 161,413 | 160,998 | 162,559 | 162,769 | 160,336 | 160,714 | 159,424 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About TGTX
TG Therapeutics, Inc. (NASDAQ: TGTX) is a stock listed on the Nasdaq Stock Market under the ticker symbol TGTX. It last traded at $61.18 (Oct 30, 2026, 4:00 PM ET), up 5.3% on the day. That gives TG Therapeutics a market capitalisation of $9.4B and a price-to-earnings ratio of 21.2.
Over the past 52 weeks TGTX has traded between $26.76 and $61.76.
Revenue for the quarter ended Mar 31, 2026 was $204.9M; net income $19.8M. Revenue was up 69.6% from $120.9M in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $204.9M | $19.8M | 9.7% |
| Dec 31, 2025 | $192.6M | $23.0M | 12.0% |
| Sep 30, 2025 | $161.7M | $390.9M | 241.7% |
| Jun 30, 2025 | $141.1M | $28.2M | 20.0% |
From TG Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…